Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Phase 2

Completed

• Conditions: Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Squamous Cell Carcinoma of the Hypopharynx
• Interventions: Drug: lapatinib ditosylate; Other: laboratory biomarker analysis

• Registration Number: NCT00098631
• Lead Sponsor: National Cancer Institute (NCI)

Brief Summary

Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. This phase II trial is studying how well lapatinib works in treating patients with recurrent and/or metastatic head and neck cancer.

Detailed Description

PRIMARY OBJECTIVES:

I. Determine the overall response rate in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with lapatinib.

II. Determine the progression-free survival, time to progression, and overall survival of patients treated with this drug.

III. Determine the toxicity of this drug in these patients.

OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 cohorts according to prior epidermal growth factor receptor-targeted therapy (yes vs no).

Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 2 months.

PROJECTED ACCRUAL: A total of 40-88 patients (21-50 epidermal growth factor receptor \[EGFR\] inhibitor-naive patients \[cohort A\] and 19-38 EGFR inhibitor-pre-treated patients \[cohort B\]) will be accrued for this study within 4-12.6 months.

Study Timeline

• Study Start: 2004-10
• Study First Submitted: 2004-12-07
• Study First Submitted QC: 2004-12-07
• Study First Posted: 2004-12-08
• Primary Completion: 2006-12
• Status Verified: 2014-01
• Last Update Submitted: 2014-01-06
• Last Update Posted: 2014-01-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

• Histologically or cytologically confirmed squamous cell carcinoma of the head and neck

  • Recurrent and/or metastatic disease

• Measurable disease

  • At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan

• No more than 2 prior treatment regimens for recurrent or metastatic disease

  • Prior chemotherapy as part of initial curative intent therapy (e.g., neoadjuvant, adjuvant, or concurrent chemotherapy) is allowed and does not count as prior therapy for recurrent or metastatic disease

• No known brain metastases

• Performance status - ECOG 0-2

• Performance status - Karnofsky 60-100%

• More than 3 months

• Bilirubin normal

• AST and ALT ≤ 2.5 times upper limit of normal

• Creatinine normal

• Creatinine clearance > 60 mL/min

• Cardiac ejection fraction normal by echocardiogram or MUGA

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

• Able to swallow and retain oral or feeding tube-administered medication

• No malabsorption syndrome

• No requirement for IV alimentation

• No uncontrolled inflammatory gastrointestinal disease (e.g., Crohn's disease or ulcerative colitis)

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No history of allergic reaction attributed to compounds of similar chemical or biologic composition to lapatinib

• No other uncontrolled illness

• No active or ongoing infection

• No psychiatric illness or social situation that would preclude study compliance

• Prior cetuximab allowed

• See Disease Characteristics

• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

• No prior cumulative anthracycline therapy ≥ 450 mg/m^2 of doxorubicin or equivalent

• More than 4 weeks since prior radiotherapy

• No prior surgical procedure affecting absorption

• Recovered from prior therapy

• Other prior epidermal growth factor receptor inhibitors (e.g., gefitinib or erlotinib) allowed

• Concurrent oral anticoagulants (e.g., warfarin) allowed provided there is increased vigilance in monitoring INR

• No concurrent CYP3A4 inhibitors or inducers

• No concurrent combination antiretroviral therapy for HIV-positive patients

• No other concurrent investigational agents

• No other concurrent anticancer therapy

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (lapatinib ditosylate)	lapatinib ditosylate	Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment (lapatinib ditosylate)	laboratory biomarker analysis	Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Objective response rate by RECIST	Up to 6 years	The 95% confidence intervals should be provided.
Progression-free survival (PFS)	From start of treatment to time of disease progression, assessed up to 6 years	Will be estimated using the Kaplan-Meier method.

Secondary Outcome Measures

Name	Time	Method
Overall survival	Up to 6 years	Will be estimated using the Kaplan-Meier method.
Changes in EGFR, pEGFR, HER2	Baseline and 12 weeks	Paired t-tests or Wilcoxon signed rank tests will be performed to examine the magnitude and significance of pre-post treatment changes. To determine whether these markers are correlated with tumor response, both the baseline levels and the pre-post changes will be compared between responders and non-responders using the nonparametric, Wilcoxon rank-sum test. The correlative data will also be entered as covariates into a Cox regression model to determine whether they are predictive of progression-free and overall survival.
Adverse events assessed using NCI CTCAE version 3.0	Up to 6 years	Adverse events will be summarized by type and grade.

Trial Locations

Locations (1)

University of Chicago Comprehensive Cancer Center; 🇺🇸 Chicago, Illinois, United States